Trazodone can cause a false-positive result for amphetamines on standard urine drug screens. There is no published large-scale study pinning down an exact percentage of how often this happens, but the mechanism is well-documented: a metabolite of trazodone closely resembles amphetamines to the antibodies used in routine screening tests. The higher your dose, the more likely the cross-reaction becomes.
Why Trazodone Triggers an Amphetamine Result
When your body breaks down trazodone, one of the byproducts is a compound called mCPP (meta-chlorophenylpiperazine). This metabolite has a chemical structure similar enough to amphetamines that standard immunoassay drug tests can’t tell the difference. Lab research testing mCPP at various concentrations found an almost perfect correlation (r = 0.990) between the amount of mCPP in a urine sample and the strength of the amphetamine signal on the test. In plain terms, more trazodone in your system means more mCPP in your urine, which means a stronger false signal.
The specific test kit matters too. The cross-reactivity has been demonstrated on the Roche Amphetamines II immunoassay, one of the widely used screening platforms. Not every brand of test kit has the same sensitivity to mCPP, so results can vary depending on which assay a lab or employer uses. The NIH’s StatPearls clinical reference explicitly lists trazodone metabolites among the known causes of false-positive amphetamine immunoassays, alongside medications like bupropion, pseudoephedrine, and phentermine.
How Often It Actually Happens
No large clinical trial has tracked thousands of trazodone users to calculate a precise false-positive rate. What exists are case reports and lab studies confirming the mechanism. We know that patients taking trazodone at therapeutic doses can produce urine with enough mCPP to trigger a positive amphetamine result, but not everyone on trazodone will test positive every time. The likelihood depends on your dose, how quickly your body metabolizes the drug, how recently you took it before the test, and which screening kit is being used.
People taking higher doses (200 to 300 mg or more) are at greater risk than those on lower doses prescribed for sleep (50 to 100 mg), simply because more trazodone produces more mCPP. Timing also plays a role. Trazodone has a relatively short half-life of 5 to 9 hours, but mCPP lingers in urine longer. If you took your dose the night before a morning test, you’re in the window where mCPP concentrations could be high enough to register.
What a False Positive Looks Like in Practice
Standard workplace, probation, and emergency room drug screens use immunoassay technology. These tests are designed to be fast and inexpensive, but they trade accuracy for speed. They work by detecting chemical shapes, not specific molecules, which is exactly why structurally similar compounds like mCPP get flagged. If you’re taking trazodone and your screening comes back positive for amphetamines, that initial result is not proof of amphetamine use. It’s a screening result that needs confirmation.
Trazodone is not known to cause false positives for other drug classes like opioids, benzodiazepines, or cannabis. The cross-reactivity is specific to amphetamine immunoassays.
Confirmatory Testing Clears It Up
A follow-up test using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) will definitively distinguish mCPP from actual amphetamines. These methods identify the exact molecular structure of what’s in your urine rather than relying on chemical similarity. In every published case where trazodone triggered a false-positive amphetamine screen, confirmatory chromatographic testing came back negative for amphetamines.
This is the key piece of information if you’re worried about a drug test: the false positive only survives the initial screening. It does not survive confirmation. Federal workplace testing guidelines and most forensic programs require a confirmatory test before any action is taken on a positive result. However, not all settings follow this standard. Some clinical programs, pain management clinics, or informal workplace policies may act on the initial immunoassay alone, which is where problems can arise.
How to Protect Yourself
If you take trazodone and know you’ll be drug tested, disclose it beforehand. Provide the name of your prescribing doctor and your pharmacy information to the medical review officer or testing coordinator. This is standard practice for any prescription medication that could interfere with drug screening. You don’t need to stop taking trazodone before a test.
If you’ve already received a positive result and suspect it’s from trazodone, request confirmatory testing by GC-MS or LC-MS. Clinical drug testing guidelines are clear that positive results should be confirmed with a more specific method before any punitive action is taken. Having your prescription records available speeds up the review process. In settings where the initial screening alone is used to make decisions, advocating for confirmation testing is especially important, because the science strongly supports that trazodone’s metabolite alone can explain the result.